Why Some Pharma Launches Soar While Others Stall

April 14, 2026

---

Over the last five years, pharmaceutical launches have become both more valuable and more fragile.

On one end of the spectrum, we’ve seen true mega-launches generate billions in record time. On the other, we’ve watched high-profile approvals struggle under the weight of reimbursement delays, infrastructure gaps, evidence uncertainty, and operational bottlenecks. The lesson is clear: approval is no longer the finish line. It is the starting point of commercialization risk. 

That is what makes today’s launch environment so challenging. Regulatory innovation remains strong, but commercial success depends less on whether a product gets approved and more on whether the organization can translate that approval into access, adoption, and sustained real-world uptake. In many markets, launch performance is now shaped by health system capacity, payer scrutiny, distribution design, and post-approval evidence generation just as much as by clinical value.

The biggest winners show what happens when demand, supply, and access align.

Eli Lilly’s tirzepatide franchise is the clearest example. Mounjaro climbed from $0.48B in 2022 to $22.97B in 2025, while Zepbound rose from $0.18B in its 2023 partial launch year to $13.54B in 2025. Those numbers reflect more than clinical excitement. They show what is possible when a product has strong differentiation and the company can scale manufacturing, expand channels, and convert demand into revenue quickly.

But blockbuster potential does not guarantee blockbuster performance.

Some of the most instructive launch stories in pharma are the products that won approval yet failed to achieve commercial escape velocity. Aduhelm became a defining case of how controversy and downstream coverage limitations can undermine a launch, even when the product enters the market with enormous attention. Roctavian showed a different problem: even after FDA approval, advanced therapies can remain commercially constrained by treatment-center readiness, payer contracting complexity, and the difficulty of identifying and moving eligible patients through the system. BioMarin reported just $36M in 2025 revenue for Roctavian before later withdrawing the product.

Other launches highlight how fragile the model becomes when the evidence base or external environment shifts. Relyvrio’s withdrawal after negative confirmatory data is a reminder that early momentum can collapse if post-approval evidence does not hold. Evusheld demonstrated that effectiveness-dependent products can hit sudden regulatory and demand cliffs when the environment changes. Zurzuvae, meanwhile, shows how even first-in-class products may encounter slower-than-expected uptake when access friction, prescriber behavior, and affordability barriers are not fully resolved.

What this means for launch leaders is simple: commercial excellence now requires system design, not just brand execution.

The most important launch questions are no longer limited to positioning and field force readiness. They now include:

• Can the product achieve broad and timely coverage?

• Is supply sufficient for real demand?

• Are channels designed around how care is actually delivered?

• Is the evidence strategy robust enough to survive payer, regulatory, and postmarketing scrutiny?

• Are teams measuring real uptake, not just top-line revenue?

  
  

That last point matters more than ever. The most rigorous launch scorecards now look beyond sales alone. They include access metrics such as time-to-coverage, demand metrics such as NBRx and patient starts, operational metrics such as fill rates and activated treatment centers, and economic metrics such as gross-to-net performance and patient affordability. In other words, the best companies are no longer asking only, “How much did we sell?” They are asking, “What is truly driving or limiting adoption?”

The playbook for future launches is becoming more defined.

Winning companies are planning for access earlier, treating capacity planning as seriously as sales planning, engineering channel activation to fit the product archetype, and managing evidence continuation as a commercial deliverable rather than a regulatory afterthought. They are also building risk mitigation plans for both sides of the equation: demand that exceeds capacity and capacity that fails to convert into demand.

The bottom line: the pharma market is not short on innovation. It is short on frictionless launch execution.

In this environment, the winners will not simply be the companies with the most promising assets. They will be the ones that understand how to connect approval, access, evidence, supply, and stakeholder activation into a launch model that actually works in the real world.